Importance: Use of chemoradiotherapy for advanced laryngeal cancer led to a major shift in treatment as an alternative to laryngectomy. Despite widespread adoption of chemoradiotherapy, survival rates have not improved and the original premise of matching neoadjuvant chemotherapy tumor response to determine subsequent treatment has not been followed. Objective: To determine whether improved survival could be achieved by incorporating a single cycle of neoadjuvant chemotherapy to select patients with advanced disease for either laryngectomy or concurrent chemoradiotherapy. Design, Setting, and Participants: An unselected cohort of 247 patients with laryngeal cancer in an academic institution between 2002 and 2012 was evaluated. Patients with limited disease (stages I and II) underwent endoscopic resection, radiotherapy, or chemoradiotherapy for deeply invasive T2 lesions. For patients with advanced disease (stages III and IV), neoadjuvant chemotherapy, concurrent chemoradiotherapy, or primary surgery was recommended. Overall survival (OS) and disease-specific survival (DSS) were analyzed. Median follow-up was 48 months. The study was conducted from January 1, 2002, to December 31, 2012; data analysis was completed December 1, 2015. Interventions: Endoscopic resection, radiotherapy, chemoradiotherapy, neoadjuvant chemotherapy, concurrent chemoradiotherapy, and primary surgery. Main Outcomes and Measures: Overall survival and DSS. Results: Of the 247 patients, 191 (77.3%) were male; mean (SD) age was 59.6 (10.4) years. Of 94 patients with limited disease, 33 (35.1%) underwent endoscopic resection; 50 (53.2%), radiotherapy alone; and 11 (11.7%), chemoradiotherapy for deeply invasive T2 lesions. Of 153 patients with advanced disease, 71 (46.4%) received neoadjuvant chemotherapy; 50 (32.7%), concurrent chemoradiotherapy; and 32 (20.9%), surgery. Five-year OS and DSS was 75% (95% CI, 68%-81%) and 83% (95% CI, 77%-88%), respectively, for the entire cohort. The DSS was 92% (95% CI, 83%-97%) for patients with stage I or II and 78% (95% CI, 69%-84%) for patients with stage III or IV disease. For patients with advanced disease, 5-year OS and DSS ranged from 78% (95% CI, 55%-90%) and 91% (95% CI, 67%-98%), respectively, for surgery; to 76% (95% CI, 63%-85%) and 79% (95% CI, 67%-88%), respectively, for neoadjuvant bioselection; and to 61% (95% CI, 44%-75%) and 66% (95% CI, 48%-79%), respectively, for primary chemoradiotherapy. Propensity-adjusted, multivariable controlling for known prognostic factors DSS was significantly improved in the neoadjuvant group compared with the chemoradiotherapy group (hazard ratio [HR], 0.48; 95% CI, 0.29-0.80). Conclusions and Relevance: Superior survival rates were achieved with a bioselective treatment approach using a single cycle of neoadjuvant chemotherapy. Good survival rates were also achieved in patients selected for primary surgery, and both neoadjuvant chemotherapy and primary surgery were better than survival rates with concurrent chemoradiotherapy, suggesting that the optimal individualized treatment approach for patients with advanced laryngeal cancer has not yet been defined.
Importance: Use of chemoradiotherapy for advanced laryngeal cancer led to a major shift in treatment as an alternative to laryngectomy. Despite widespread adoption of chemoradiotherapy, survival rates have not improved and the original premise of matching neoadjuvant chemotherapy tumor response to determine subsequent treatment has not been followed. Objective: To determine whether improved survival could be achieved by incorporating a single cycle of neoadjuvant chemotherapy to select patients with advanced disease for either laryngectomy or concurrent chemoradiotherapy. Design, Setting, and Participants: An unselected cohort of 247 patients with laryngeal cancer in an academic institution between 2002 and 2012 was evaluated. Patients with limited disease (stages I and II) underwent endoscopic resection, radiotherapy, or chemoradiotherapy for deeply invasive T2 lesions. For patients with advanced disease (stages III and IV), neoadjuvant chemotherapy, concurrent chemoradiotherapy, or primary surgery was recommended. Overall survival (OS) and disease-specific survival (DSS) were analyzed. Median follow-up was 48 months. The study was conducted from January 1, 2002, to December 31, 2012; data analysis was completed December 1, 2015. Interventions: Endoscopic resection, radiotherapy, chemoradiotherapy, neoadjuvant chemotherapy, concurrent chemoradiotherapy, and primary surgery. Main Outcomes and Measures: Overall survival and DSS. Results: Of the 247 patients, 191 (77.3%) were male; mean (SD) age was 59.6 (10.4) years. Of 94 patients with limited disease, 33 (35.1%) underwent endoscopic resection; 50 (53.2%), radiotherapy alone; and 11 (11.7%), chemoradiotherapy for deeply invasive T2 lesions. Of 153 patients with advanced disease, 71 (46.4%) received neoadjuvant chemotherapy; 50 (32.7%), concurrent chemoradiotherapy; and 32 (20.9%), surgery. Five-year OS and DSS was 75% (95% CI, 68%-81%) and 83% (95% CI, 77%-88%), respectively, for the entire cohort. The DSS was 92% (95% CI, 83%-97%) for patients with stage I or II and 78% (95% CI, 69%-84%) for patients with stage III or IV disease. For patients with advanced disease, 5-year OS and DSS ranged from 78% (95% CI, 55%-90%) and 91% (95% CI, 67%-98%), respectively, for surgery; to 76% (95% CI, 63%-85%) and 79% (95% CI, 67%-88%), respectively, for neoadjuvant bioselection; and to 61% (95% CI, 44%-75%) and 66% (95% CI, 48%-79%), respectively, for primary chemoradiotherapy. Propensity-adjusted, multivariable controlling for known prognostic factors DSS was significantly improved in the neoadjuvant group compared with the chemoradiotherapy group (hazard ratio [HR], 0.48; 95% CI, 0.29-0.80). Conclusions and Relevance: Superior survival rates were achieved with a bioselective treatment approach using a single cycle of neoadjuvant chemotherapy. Good survival rates were also achieved in patients selected for primary surgery, and both neoadjuvant chemotherapy and primary surgery were better than survival rates with concurrent chemoradiotherapy, suggesting that the optimal individualized treatment approach for patients with advanced laryngeal cancer has not yet been defined.
Authors: C R Bradford; G T Wolf; T E Carey; S Zhu; T F Beals; J M Truelson; K D McClatchey; S G Fisher Journal: Otolaryngol Head Neck Surg Date: 1999-11 Impact factor: 3.497
Authors: Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316
Authors: Maria M LoTempio; Kevin H Wang; Ahmed Sadeghi; Mark D Delacure; Guy F Juillard; Marilene B Wang Journal: Otolaryngol Head Neck Surg Date: 2005-06 Impact factor: 3.497
Authors: Sara Meade; Paul Sanghera; Christopher McConkey; Jack Fowler; George Fountzilas; John Glaholm; Andrew Hartley Journal: Int J Radiat Oncol Biol Phys Date: 2013-01-17 Impact factor: 7.038
Authors: Carol R Bradford; Bhavna Kumar; Emily Bellile; Julia Lee; Jeremy Taylor; Nisha D'Silva; Kitrina Cordell; Celina Kleer; Robbi Kupfer; Pawan Kumar; Susan Urba; Francis Worden; Avraham Eisbruch; Gregory T Wolf; Theodoros N Teknos; Mark E P Prince; Douglas B Chepeha; Norman D Hogikyan; Jeffrey S Moyer; Thomas E Carey Journal: Laryngoscope Date: 2013-07-12 Impact factor: 3.325
Authors: Theodoros N Teknos; Claudell Cox; Martin A Barrios; Douglas B Chepeha; Carol R Bradford; Susan G Fisher; Gregory T Wolf Journal: Laryngoscope Date: 2002-05 Impact factor: 3.325
Authors: Michael L Hinni; John R Salassa; David G Grant; Bruce W Pearson; Richard E Hayden; Alexios Martin; Hans Christiansen; Bruce H Haughey; Brian Nussenbaum; Wolfgang Steiner Journal: Arch Otolaryngol Head Neck Surg Date: 2007-12
Authors: Danielle L Gainor; Emily Marchiano; Emily Bellile; Matthew E Spector; Jeremy M G Taylor; Gregory T Wolf; Norman D Hogikyan; Mark E Prince; Carol R Bradford; Avraham Eisbruch; Francis Worden; Andrew G Shuman Journal: Otolaryngol Head Neck Surg Date: 2017-06-13 Impact factor: 3.497
Authors: Connor W Hoban; Lauren J Beesley; Emily L Bellile; Yilun Sun; Matthew E Spector; Gregory T Wolf; Jeremy M G Taylor; Andrew G Shuman Journal: Cancer Date: 2017-11-07 Impact factor: 6.860
Authors: Carol R Bradford; Alfio Ferlito; Kenneth O Devaney; Antti A Mäkitie; Alessandra Rinaldo Journal: Laryngoscope Investig Otolaryngol Date: 2020-01-27
Authors: Laila A Gharzai; Julia Pakela; Elizabeth M Jaworski; Issam El Naqa; Jennifer Shah; Peter G Hawkins; Matthew E Spector; Carol R Bradford; Steven B Chinn; Kelly Malloy; Robbi Kupfer; Andrew Shuman; Robert Morrison; Chaz L Stucken; Andrew Rosko; Mark E Prince; Keith Casper; Avraham Eisbruch; Gregory Wolf; Paul L Swiecicki; Francis Worden; Michelle L Mierzwa Journal: Clin Transl Radiat Oncol Date: 2021-12-23
Authors: Valentina D A Corino; Marco Bologna; Giuseppina Calareso; Carlo Resteghini; Silvana Sdao; Ester Orlandi; Lisa Licitra; Luca Mainardi; Paolo Bossi Journal: J Imaging Date: 2022-02-15
Authors: Michael M Li; Songzhu Zhao; Antoine Eskander; Chandler Rygalski; Guy Brock; Anuraag S Parikh; Catherine T Haring; Brian Swendseid; Kevin Y Zhan; Carol R Bradford; Theodoros N Teknos; Ricardo L Carrau; Kyle K VanKoevering; Nolan B Seim; Matthew O Old; James W Rocco; Sidharth V Puram; Stephen Y Kang Journal: Ann Surg Oncol Date: 2021-07-15 Impact factor: 4.339